BNET Industries
Market Cap:$99.9B
Last Fiscal Year Sales:$32.9B
- Public
- FR
Dow Jones Description
Sanofi-Aventis sees the future - where disease is in the past. Formed by a 2004 merger and headquartered in Paris, France, Sanofi-Aventis (NYSE: SNY (ADR) Euronext Paris: SAN) is the third-largest pharmaceutical maker in the world. The company researches, develops, manufactures, and markets prescription drugs. Its products include Allegra, Aprovel, Eloxatin, Lovenox, Nasacort, Plavix, Taxotere, and Tritace, among others. It has over 100 compounds in development, about 40 of which are in Phase II or III clinical trials. The company has annual revenue of about A28.5 billion and employs about 100,000 people. In March 2006 the company acquired almost 25% of Zentiva NV for approximately A430 million. In 2005 the company sold its interests in Wacker-Chemie.
Number of Employees 97,181
Peer Companies
NAICS Code Drugs and Druggists' Sundries Merchant Wholesalers: 424210
Recent Events
-
Sanofi-Aventis SNY Announces Agreement with Intelliject for Novel Epinephrine Auto Injector
-
The Side Effect of Developing Obesity Drugs
-
Drugmakers' Differences: Analyst's Toolkit
-
Deutsche Bank Initiates Coverage on Sanofi-Aventis SNY with a Buy
-
Big Pharma Willing to Pay for Biotech Innovation
-
Sanofi-Aventis names Spek global operations head 37 mins ago
-
Sanofi-Aventis Q3 Profit Rises; Lifts FY09 Adj. EPS Growth View; To Buy Laboratoire Oenobiol -...
-
UPDATE 3-Sanofi lifts forecast on swine flu vaccine
-
Sanofi-Aventis and Micromet to Develop New Tumour Antibody
-
Dyax Corp. Q3 2009 Earnings Call Transcript
-
Sanofi-Aventis's New JV Will Provide Entry into Chinas OTC Market
-
Mexico pushing for homegrown swine flu vaccine
-
Sanofi cozies up to Wellstat for $350M diabetes insulin pact
-
Sanofi-Aventis France (SASY.PA) Buys Wellstat Therapeutics Corporation's Type II Diabetes Drug PN2034 For Up To...
-
Wellstat Therapeutics and Sanofi-aventis Enter Agreement On Novel Therapy for Type II Diabetes
-
Notable Analyst Rating Changes 10/14: CSC, GSK, SNY, ABX, CNO, HOG, TEL Upgrade; VLO, JBLU,...
-
Sanofi-Aventis France (SASY.PA) to Buy Dyax Corp. DYAX's Drug Development Partner, Fovea Pharmaceuticals
-
BRIEF-Credit Suisse raises targets on European pharma cos
-
Sanofi to launch own generic version of Plavix
News & Analysis
Filter by
investment and sanofi-aventis - All News and Analysis
Should Sanofi-Aventis Buy Bristol Myers-Squibb?
BNET
- 2008-10-27
Bristol-Myers Squibb CEO James Cornelius said in a recent earnings call that due to its healthy cash position it may be on the prowl for biotech acquisitions. That's ironic because it is looking more like BMS itself could be the company to be acquired, possibly by Sanofi-Aventis. ...
Sanofi strikes back in takeover battle for big Czech drug company
- 2008-06-18
PRAGUE AFP — Czech-based generic drugs giant Zentiva was at the heart of a takeover tussle Wednesday after French group Sanofi-Aventis struck back with an offer countering a bid by local financial concern PPF. PPF, holding a 19.2 percent stake in Zentiva, which has substantial markets in Slovakia, Romania...
Hirings; Alabama College Tuition.(GlaxoSmithKline PLC hired ABN AMRO Mellon Global Securities Services)(Halliburton Co hired State Street Corp)(Methuen Contributory Retirement System hired DuPont Capital Management )
- 2005-10-17
MONTGOMERY, Ala. - The $650 million Alabama Prepaid Affordable College Tuition Program hired Western Asset Management to run $120 million in core-plus fixed income and INTECH to manage $80 million in active domestic large-cap growth equities, said An MONTGOMERY, Ala. - The $650 million Alabama Prepaid...
SAP, Sanofi-Aventis expand operations in Hungary
- 2005-07-01
BUDAPEST AFP — SAP, the world's leading maker of business software, and French pharmaceuticals firm Sanofi-Aventis expanded their business operations in Hungary. The German group SAP laid the foundations of a new research and development center in Budapest, its 10th worldwide, which is due to open by year's end,...
Sanofi-Aventis posts 18 pct profit rise in 2004, sees in-line 2005
- 2005-03-01
PARIS AFP — Sanofi-Aventis, the French pharmaceutical firm, posted forecast-beating net profit for 2004 and said it expected earnings this year to be in line with the 2004 performance. Sanofi-Aventis, formed last year in the merger of French firm Sanofi Synthelabo and Franco-German life sciences giant Aventis, said it...
- 1
| Volume | 852,754 |
| Shares Outstanding | 2.6B |
| Market Cap | 99.9B |
| Year High | 40.17 |
| Year Low | 24.59 |
| Earnings Per Share | 2.21 |
| P/E Ratio | 17.1765 |
| Dividend | 1.0639 |
| Yield | 2.80 |
Industry Transcripts by Seeking Alpha
-
Avanir Pharmaceuticals F4Q09 (Qtr End 09/30/2009) Earnings Call Transcript
on Nov 24, 2009about AVNR
-
Palatin Technologies F1Q10 (Qtr End 9/30/09) Earnings Call Transcript
on Nov 16, 2009about PTN
-
Flamel Technologies SA Q3 2009 Earnings Call Transcript
on Nov 16, 2009about FLML
-
NexMed Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about NEXM
-
InterMune, Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about ITMN
IndustryTop Rated
- How NOT to Write a Biotech Press Release: Just Ask Epeius 5 votes
- Biogen Idec's Social Media Ties Save Tysabri Again; FDA Watching 3 votes
- Teva, In Turnabout, Sues to Protect Its Multiple Sclerosis Drug Copaxone 3 votes
- BioCryst's Antiviral Drug Peramivir Aims to Keep Swine-Flu Body Count Low 3 votes
- More Tysabri Problems; Time for a Biogen-Idec Credibility Check 3 votes
